Thematic Exposure -- 8/10
McKesson is one of three wholesalers -- with Cencora and Cardinal Health -- that control more than
90% of US pharmaceutical distribution, a textbook entrenched oligopoly with ~33% individual share.
Its largest segment, North American Pharmaceutical (~83% of revenue), grows at/above GDP with
structurally expanding operating profit, and its fastest-growing exposure -- Oncology &
Multispecialty (+31% FY2026) -- rides a double-digit specialty/oncology theme where MCK is a
co-leader. The oligopoly hard gate is PASSED. The score is held at 8 rather than 10 because the
dominant book is a razor-thin-margin, price-taking distribution business rather than a dominant-share
pricing-power monopoly, and the Med-Surg tail is fragmented and being spun off.
Weight: 35%
Pharmaceutical Distribution Oligopoly -- The Core Theme
Entrenched Oligopoly -- Durable, GDP-Plus
The Big 3 (McKesson, Cencora, Cardinal Health) control more than 90% of US pharmaceutical
distribution, each holding roughly 30%+ share. There is no at-scale fourth national entrant.
Volume grows at/above GDP, driven by specialty and GLP-1 mix, with structurally expanding
adjusted operating profit. This is the definition of a rational, non-destructive oligopoly.
Oncology & Multispecialty -- The Growth Layer
High-Growth Theme -- +31% FY2026
MCK is widely considered the community-oncology distribution leader (co-leader with Cencora),
and it is actively vertically integrating into the provider demand side. The segment grew +31%
in FY2026 on a double-digit specialty/oncology theme -- the fastest-growing exposure in the
portfolio and a genuine, durable growth driver layered on top of the distribution oligopoly.
Medical-Surgical -- Fragmented and Being Spun
Sub-Scale Tail -- Separation Announced
The Medical-Surgical unit (~3% of revenue) sits in a genuinely fragmented market -- the top-5
players hold roughly 20% combined, none above 15%. It is the one non-oligopolistic part of the
book, and management has announced it will separate it into an independent company (H2 2027).
Divesting the fragmented tail sharpens the distribution mix.
Segment Exposure, Share, TAM & Theme Growth
| Segment | % Rev (FY26) | Market Share | TAM | Theme Growth |
|---|---|---|---|---|
| NA Pharmaceutical | 83.5% | ~33% (1 of Big 3 = ~90-95% combined) | US pharma ~$520-720B | GDP+ volume; specialty/GLP-1 driven |
| Oncology & Multispecialty | 12.0% | Community-oncology leader (with Cencora) | US oncology drugs ~$105-116B | High; segment +31% FY2026 |
| Prescription Tech (RxTS) | 1.4% | Niche tech platform (prior-auth/adherence) | Access/affordability, low tens of $B | Double-digit op-profit growth |
| Medical-Surgical | ~2.9% | Under 10% (top-5 ~20% combined) | Healthcare distribution, fragmented | Low; to be spun off H2 2027 |
Total FY2026 revenue $403.4B; segments do not sum exactly to 100% due to International/other.
Three Required Questions
| # | Question | Answer |
|---|---|---|
| 1 | Competitors above 15% share per segment? | NA Pharmaceutical: only ~3 players, each near ~30%+ -- concentrated, NOT fragmented. Oncology: effectively 2 dominant players (MCK, Cencora). Med-Surg: fragmented (top-5 ~20% combined, none above 15%). The core ~96% of revenue is oligopolistic; only the ~3% Med-Surg tail is fragmented (and being divested). |
| 2 | Could a customer replace MCK within 12 months? | No -- multi-year contracts, deep workflow integration, and the absence of a fourth at-scale national distributor make switching impractical within a year. Moat intact. |
| 3 | Price-setter or price-taker? | Price-taker on the underlying drug (distribution is a fee/spread business with thin gross margins), but the Big 3 collectively set distribution-fee terms in a stable three-way market -- rational, non-destructive pricing typical of an oligopoly, not a fragmented price war. |
Oligopoly Gate
| Criterion | Result |
|---|---|
| MCK share in US pharma distribution | ~33% |
| Big 3 combined share | > 90% |
| Three or fewer players controlling > 70%? | Yes |
| Key competitors | Cencora, Cardinal Health |
| Gate result | PASS |
8/10 — The thesis rests on a durable,
GDP-plus pharmaceutical-distribution oligopoly (~83% of revenue, ~33% share, Big 3 controlling more
than 90%) layered with a genuinely high-growth specialty/oncology theme (+31% in FY2026) where MCK
is a co-leader actively vertically integrating into the provider demand side. Customers cannot
realistically defect within a year, and there is no at-scale fourth entrant. The position falls
short of a perfect 10 only because the dominant business is a low-margin, price-taking distribution
franchise (not a dominant-share pricing-power monopoly) and because the smaller Med-Surg unit is
genuinely fragmented and being spun off.
Data sourced from Daloopa (company_id: 482). Market-share/TAM data from IntuitionLabs, Drug Channels, VMG Health, Morningstar, Statista, and Precedence Research via web search.